TWI780069B - 用於病毒專一性t細胞之活化及增生的平台 - Google Patents

用於病毒專一性t細胞之活化及增生的平台 Download PDF

Info

Publication number
TWI780069B
TWI780069B TW106131831A TW106131831A TWI780069B TW I780069 B TWI780069 B TW I780069B TW 106131831 A TW106131831 A TW 106131831A TW 106131831 A TW106131831 A TW 106131831A TW I780069 B TWI780069 B TW I780069B
Authority
TW
Taiwan
Prior art keywords
cells
virus
antigen
specific
peptides
Prior art date
Application number
TW106131831A
Other languages
English (en)
Chinese (zh)
Other versions
TW201814041A (zh
Inventor
克里歐納Ｍ 魯尼
那塔利亞Ｌ 多伊爾
桑德亞 莎瑪
戴米崔歐斯Ｌ 瓦格納
Original Assignee
貝勒醫學院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 貝勒醫學院 filed Critical 貝勒醫學院
Publication of TW201814041A publication Critical patent/TW201814041A/zh
Application granted granted Critical
Publication of TWI780069B publication Critical patent/TWI780069B/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
TW106131831A 2016-09-16 2017-09-15 用於病毒專一性t細胞之活化及增生的平台 TWI780069B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662395438P 2016-09-16 2016-09-16
US62/395,438 2016-09-16

Publications (2)

Publication Number Publication Date
TW201814041A TW201814041A (zh) 2018-04-16
TWI780069B true TWI780069B (zh) 2022-10-11

Family

ID=61619728

Family Applications (1)

Application Number Title Priority Date Filing Date
TW106131831A TWI780069B (zh) 2016-09-16 2017-09-15 用於病毒專一性t細胞之活化及增生的平台

Country Status (10)

Country Link
US (2) US20190194619A1 (https=)
EP (1) EP3512531A4 (https=)
JP (1) JP7002769B2 (https=)
KR (1) KR102501827B1 (https=)
CN (1) CN110177558B (https=)
AU (1) AU2017326173B2 (https=)
CA (1) CA3036966A1 (https=)
NZ (1) NZ751571A (https=)
TW (1) TWI780069B (https=)
WO (1) WO2018052947A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3101122B1 (en) 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
PT2812431T (pt) 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
JP6999941B2 (ja) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン 病原体からの免疫原性抗原同定および臨床的有効性との相関
US9642906B2 (en) * 2016-09-16 2017-05-09 Baylor College Of Medicine Generation of HPV-specific T-cells
CN116970059A (zh) 2016-12-22 2023-10-31 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
TW202011977A (zh) * 2018-04-20 2020-04-01 貝勒醫學院 溶瘤病毒療法及免疫療法
CN108841792A (zh) * 2018-06-14 2018-11-20 浙江大学 靶向cd19和ebna1基因修饰的t细胞及其制备方法与应用
ES3000183T3 (en) * 2018-09-10 2025-02-27 Atara Biotherapeutics Inc Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
US10772914B1 (en) * 2019-04-18 2020-09-15 Baylor College Of Medicine EBV-specific immune cells
WO2022056285A1 (en) * 2020-09-10 2022-03-17 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
EP4048402A4 (en) * 2019-10-23 2023-11-22 Cue Biopharma, Inc. MODIFIED CYTOTOXIC T CELLS AND METHOD OF USE THEREOF
WO2021101466A1 (en) * 2019-11-19 2021-05-27 Acibadem Labmed Sağlik Hi̇zmetleri̇ A.Ş. A method for producing multivirus specific t cells
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors cd19 and cd22 and their uses
WO2021221927A1 (en) 2020-04-27 2021-11-04 Parsons Corporation Narrowband iq signal obfuscation
TW202208395A (zh) 2020-05-12 2022-03-01 美商信號生物製藥公司 多聚體ｔ細胞調節多肽及其使用方法
CN116391030A (zh) * 2020-10-28 2023-07-04 Tsd 生命科学有限公司 诱导异质免疫细胞趋化的转化免疫细胞
CN117529551A (zh) 2021-04-27 2024-02-06 贝勒医学院 表达嵌合抗原受体的病毒特异性免疫细胞
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR20250024750A (ko) 2022-04-13 2025-02-19 티크바 알로셀 피티이. 엘티디. 치료용 t 세포 산물
EP4509137A1 (en) * 2023-06-14 2025-02-19 Kuiper, Inc. A chimeric antigen receptor combinatorial multi-antigen targeted allogeneic t cell immunotherapy with reduced risk of t cell exhaustion, host versus graft rejection, and graft versus host disease
GB202318977D0 (en) * 2023-12-12 2024-01-24 Swarm Oncology Ltd Method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273122A (zh) * 2005-08-08 2008-09-24 塔博尔山圣拉弗尔基金中心 普通γ链细胞因子在记忆T淋巴细胞的显影、分离和遗传修饰中的应用
WO2016044853A1 (en) * 2014-09-19 2016-03-24 City Of Hope Central memory t cells for adoptive t cell therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155594A1 (en) 2001-03-27 2002-10-24 Hsieh Helen V. Method and apparatus for culturing cells
CA2682527C (en) * 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred t lymphocytes
EP2065462A1 (en) * 2007-11-27 2009-06-03 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Ex vivo method for producing a preparation containing CD4+ T cells specific for EBV structural antigens
WO2010119307A1 (en) * 2009-04-14 2010-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for stimulating antigen-specific t cell responses using accelerated co-cultured dendritic cells
EP3101122B1 (en) * 2009-08-24 2023-06-14 Baylor College of Medicine Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses
CN103002915B (zh) * 2010-04-13 2015-09-23 免疫创新治疗有限公司 抑制Treg细胞的方法和组合物
CN104769104A (zh) * 2011-12-12 2015-07-08 细胞药物有限公司 扩大t细胞的方法
PT2812431T (pt) * 2012-02-09 2019-10-18 Baylor College Medicine Pepmixes para gerar ctls multivirais com larga especifidade
KR101545217B1 (ko) * 2012-10-29 2015-08-18 연세대학교 산학협력단 줄기세포의 미분화 배양 및 분화 증진을 위한 폴리도파민-펩타이드 고정화 표면 기질 및 그 제조 방법
CN105335280A (zh) * 2014-07-16 2016-02-17 北京奇虎科技有限公司 程序性能测试方法和装置
CA2984624A1 (en) * 2015-03-18 2016-09-22 Baylor College Of Medicine Her2/erbb2 chimeric antigen receptor
US12478670B2 (en) * 2015-03-20 2025-11-25 Children's National Medical Center Generating HPV antigen-specific T cells from a naïve T cell population
JP7284556B2 (ja) * 2015-05-12 2023-05-31 メモリアル スローン ケタリング キャンサー センター Ｔ細胞療法によるエプスタイン－バーウイルス関連リンパ増殖性障害の治療方法
AU2016274633B2 (en) * 2015-06-09 2022-04-21 Gammadelta Therapeutics Ltd Methods for the production of TCR gamma delta+ T cells
MX2019000022A (es) * 2016-06-27 2019-09-18 Yeda Res & Dev Células veto generadas a partir de linfocitos t de memoria.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101273122A (zh) * 2005-08-08 2008-09-24 塔博尔山圣拉弗尔基金中心 普通γ链细胞因子在记忆T淋巴细胞的显影、分离和遗传修饰中的应用
WO2016044853A1 (en) * 2014-09-19 2016-03-24 City Of Hope Central memory t cells for adoptive t cell therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
期刊 S Lam, et al., "Developing Multi-HIV Antigen Specific T Cells as a Component of a Cure Strategy." , 2015/11/01, jpt.com, https://www.jpt.com/media/03/e8/6e/1617873646/AppNote_Immunology_ HIV_ULTRA_Peptide_Pool. pdf *

Also Published As

Publication number Publication date
NZ751571A (en) 2025-10-31
AU2017326173B2 (en) 2022-08-18
KR20190051039A (ko) 2019-05-14
KR102501827B1 (ko) 2023-02-22
CN110177558B (zh) 2025-02-28
US20220251509A1 (en) 2022-08-11
TW201814041A (zh) 2018-04-16
CA3036966A1 (en) 2018-03-22
EP3512531A1 (en) 2019-07-24
AU2017326173A1 (en) 2019-04-11
JP7002769B2 (ja) 2022-02-04
EP3512531A4 (en) 2020-03-11
JP2019531722A (ja) 2019-11-07
WO2018052947A1 (en) 2018-03-22
US20190194619A1 (en) 2019-06-27
CN110177558A (zh) 2019-08-27

Similar Documents

Publication Publication Date Title
TWI780069B (zh) 用於病毒專一性t細胞之活化及增生的平台
US10500265B2 (en) Generation of HPV-specific T-cells
US11981923B2 (en) Pepmixes to generate multiviral CTLS with broad specificity
JP2021503959A (ja) がんおよび関連悪性腫瘍の治療のためのγδＴ細胞を活性化、修飾、および増殖させる方法
Rooney et al. T lymphocytes targeting native receptors
JP2025028931A (ja) Ｅｂｖ特異的免疫細胞
CA3028168C (en) Compositions and methods for activating antigen presenting cells with chimeric poliovirus
NZ791258A (en) Platform for activation and expansion of virus-specific t-cells
Orentas et al. 72: Effective immunotherapy for neuroblastoma requires HSCT and T cell transfer
Myers et al. 71: Virus-specific T cells engineered to co-express tumor-specific receptors; effects in patients with neuroblastoma

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent